OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director exercised or converted 20K CYTK derivative securities | OQRO

Home
Insider trades
Cytokinetics
Director exercised or converted 20K CYTK derivative securities

Insider trades

Insider trade

Director exercised or converted 20K CYTK derivative securities

Traded Dec 1, 2025 · Filed Dec 2, 2025

CYTCytokineticsCYTK

20K
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 1, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 2, 2025

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-25-000040

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Dec 2, 2025, 2:18 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Edward M. Md Kaye

Relationship

Director

Security

Non-Qualified Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Dec 1, 2025

Transaction code

Shares / units

20,000

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

Ownership form

Direct

Amendment

Footnotes from the filing

This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018.

Around the same time

Andrew Callos (EVP, Chief Commercial Officer) sold ~$113K of Cytokinetics

Automatic saleFiled 9mo ago

Robert I BlumPresident & CEO

Filed 9mo ago

5,765Shares

Traded Dec 22, 2025 · filed 7 days later

Compensation award — excluded from discretionary-purchase analysis.

More Official record

Robert I BlumPresident & CEO

Filed 9mo ago

5,765Shares

Traded Dec 22, 2025 · filed 7 days later

Compensation award — excluded from discretionary-purchase analysis.

More Official record